Most Favored Nation Pricing, Tariffs & the Rise of China | Neil Grubert | EP 8

Most Favored Nation (MFN) drug pricing, pharma tariffs, and China overtaking the US in new drug launches: on this episode of The Pharma Perspective, market access and policy expert Neil Grubert breaks down the forces reshaping how the world prices and pays for medicines. Neil explains what Trump's Executive Order on Most Favored Nation pricing really means, why the US funds an estimated 75% of global pharmaceutical profits, and how tariffs are being used to pressure drug companies and governments. He also unpacks the EU Pharmaceutical Package, Europe's growing launch hesitancy, and the moment when China overtook the US in new medicines brought to market, before closing on what he would change about global drug pricing. Essential viewing for anyone in pharma, market access, HEOR, health policy, or life sciences.